Zhejiang Haisen Pharmaceutical Co., Ltd.

On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Zhejiang Haisen Pharmaceutical Co., Ltd.

26 YRS

Zhejiang, China

CNY 11 Million

149850 m²

500-1000 people

Main Products: Metamizole Sodium / Sucralfate / Antipyrine / Aminopyrine / 2-Hydroxy-4-Amino Butanoic Acid / L-Glutamine / Paroxetine Hydrochloride / Atorvastatin Calcium / Parecoxib Sodium / Propyphenazone / Paroxetine

Zhejiang, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

VERIFIEDMANUFACTURINGCOMPANY

Business Type

Manufacturing

Total Employees

500-1000 People

Plant Size

225 Acres

Total Annual Revenue

CNY 300 Million

Production Experience

26+ Years

MAIN
PRODUCTS

1/1

Metamizole Sodium

CAS: 68-89-3

Packing: 25 KG/Fibre Drum

Lead Time: 14-30 days

Inquiry

1/1

Sucralfate

CAS: 54182-58-0

Packing: 25 KG/Fibre Drum

Lead Time: 14-30 days

Inquiry

1/1

Antipyrine

CAS: 60-80-0

Packing: 25 KG/Fibre Drum

Lead Time: 14-30 days

Inquiry

ABOUT US

Zhejiang Haisen Pharmaceutical Co., Ltd.

Zhejiang Haisen Pharmaceutical Co., Ltd. is located in Liushi street, Dongyang city Zhejiang province. It is a medium scale enterprise which mainly engages in the R&D, production and operation of API and pharmaceutical intermediates. It is a state hi-tech enterprise, covering an area of 70,000 square meters and with fixed capital of RMB 230 million and over 450 employees including 32% professional technicians. The company passed ISO9001:2000 international quality system certification in 2001.In 2006, it passed the GMP certification for the first time in China. In the same year, it obtained the CEP certificate of EU. In 2014, it passed the on-site audit of FDA for the first time in the US. The main products of the company are API: Saccharide, Analgin, Pazufloxacin mesylate, Atorvastatin Calcium, Paroxetine Hydrochloride, Escitalopram Oxalate;Intermediates: PHBA, methylparoxetine, etc.At present, many varieties have been registered in the United States, the European Union, Japan, South Korea, India, Brazil, Mexico and other countries.Among them, sucrose and aluminum products occupy more than 60% of the world market. Adhering to the quality and environment policy of "customer first, environment first, quality leading, continuous improvement", the company continues to increase the research and development of high-tech and investment efforts, from which more economic benefits and growth points.Company and the sichuan antibiotic industrial research institute, Shanghai medical professionals hospital, tianjin drug research institute, zhejiang university and other research institutions established good long-term cooperative relations for many years, zhejiang provincial technology center, member of hazen drug research institute of zhejiang province and hazen pharmaceutical experts workstation has formed, the company leading domestic technology center of research and development level has reached with the field.Escitalopram oxalate tablets (trademark Taqi), jointly developed b